Editorial Open Access
Volume 7 | Issue 4 | DOI: https://doi.org/10.33696/cancerimmunol.7.117
Re-engineering the Tumor–Immune Interface—Emerging Frontiers in Cancer Immunology and Immunotherapy
Sanjay K. Srivastava1,*
- 1Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, Abilene, Texas, USA
Corresponding Author
Sanjay K. Srivastava, Sanjay.Srivastava@ttuhsc.edu
Received Date: November 28, 2025
Accepted Date: December 12, 2025
Srivastava SK. Re-engineering the Tumor–Immune Interface—Emerging Frontiers in Cancer Immunology and Immunotherapy. J Cancer Immunol. 2025;7(4):181–182.
Copyright: © 2025 Srivastava SK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Prevalence of Symptom Clusters in Cancer Patients at First Presentation in Palliative Care Clinic as per Different Disease Groups
Cancer has its own disease burden and patients usually suffer from symptom clusters when they are referred for palliative treatment. Identification of symptom cluster trajectories will help clinician to take into account measures that can optimize quality of life of palliative patients. Therefore the aim of this paper is to determine the overall prevalence of symptoms and symptoms clusters in different disease groups according to etiology at the time of first visit to Palliative care clinic by using HIS Palliative First Assessment note indicating Edmonton symptom scale.
Chimeric Antigen Receptor CAR NK Cells Emerging Immunotherapy for the Treatment of Cancer
Although NK cells are recognized as effector lymphocytes of the innate immune system, they also regulate the adaptive immune response by releasing inflammatory cytokines and developing immunological memory. Unlike other lymphocytes such as T or B cells, NK cells do not express rearrangeable, antigen-specific receptors.
Emerging Role of TRPML1 Mucolipin Endolysosomal Channel in Cancer
The transient receptor potential mucolipin 1 (TRPML1) is an endolysosomal channel belonging to the TRP family. Clinically, mutations of TRPML1 have been responsible for a severe lysosomal storage disorder called mucolipidosis type IV.
Uniportal VATS Lobectomy for Lung Cancer: Feasibility and Cost Effectiveness in a Single Center Experience
In last decades, video-assisted thoracic surgery (VATS) together with robotic-assisted thoracic surgery (RATS) can be considered the biggest innovation in thoracic surgery. This approach drastically changed the way of performing surgical operations, improving patient’s outcome undergoing thoracic surgery.
Circulating Cell-Free RNA: A New Perspective for Endometrial Cancer
In order to implement the knowledge of cancer to monitor its evolution and setting, in the last decade, new minimally invasive and repeatable samples collection have been developed such as liquid biopsy. Cancer biomarkers originating from tumors can represent the molecular status of the tumor or its metastases which release them directly into body fluids or indirectly due to disruption of tumor/metastatic tissue. These biomarkers are detectable in liquid biopsy.